Skip to main content
. 2020 Aug 12;9(5):549–562. doi: 10.1159/000508485

Table 5.

Sensitivity analysis considering different QALY weights

Treatments: 1. = 1st-line 2. = 2nd-line Average QALYs CER
1. Sorafenib
2. Regorafenib		 0.511 283,794.44
1. Sorafenib
2. Cabozantinib		 0.517 287,561.28
1. Sorafenib
2. Pembrolizumab		 0.527 244,598.35
1. Sorafenib
2. Nivolumab		 0.532 256,385.71
1. Lenvatinib
2. Regorafenib		 0.557 274,541.24
1. Lenvatinib
2. Cabozantinib		 0.561 277,236.79
1. Lenvatinib
2. Pembrolizumab		 0.570 246,349.26
1. Lenvatinib
2. Nivolumab		 0.573 255,414.08

CER, cost effectiveness ratio; QALY, quality-adjusted life years.